{'fraction_non_alphanumeric': 0.03424056189640035, 'fraction_numerical': 0.016681299385425813, 'mean_word_length': 5.031746031746032, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Treatment of epileptic seizures resistant to phenobarbital in children during the first year of life].

In a prospective investigation, efficacy and safety of use of valproate (depakine-syrup) was studied in infants presenting with the epileptic convulsive syndrome that was resistant to phenobarbital. The study comprised 26 patients who ranged from 3 months to 1 year old presenting with primary and secondary generalized convulsive epileptic fit. The use of valproate (depakine-syrup) in a medium therapeutic dose (15 +/- 5) mg/kg per day permitted controlling fits in sixteen babies (61.53%) over six weeks; in other three infants (11.53%) the frequency of paroxysms has come to be strikingly decreased, in one infant (3.84%) there has been achieved only partial control of fits, and it is only in 6 babies that the state remained unchanged. In this way, the use of valproate (depakine-syrup) in babies presenting with primary and secondary generalized cerebral seizure resistant to phenobarbital is an effective means of control of seizures with lesser incidence of ill effects recordable than in case of employment of phenobarbital.